Latanoprost Yonsung

Latanoprost, the active ingredient in Latanoprost Yonsung, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It treats open-angle glaucoma and ocular hypertension by lowering intra‑ocular pressure.\n\nGNH India supplies Latanoprost Yonsung as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost Yonsung belongs to the prostaglandin analog class and is used to manage conditions that involve elevated intra‑ocular pressure.\n\nOpen-angle glaucoma: reduces intra‑ocular pressure to slow disease progression.\nOcular hypertension: lowers elevated eye pressure to prevent development of glaucoma.\nElevated intra‑ocular pressure: assists in maintaining normal pressure levels in at‑risk patients.

Latanoprost may cause ocular and systemic reactions.\n\nCommon Side Effects:\n- Eye redness or hyperemia\n- Increased eyelash growth\n- Darkening of the iris color\n- Eye irritation or foreign‑body sensation\n- Blurred vision\n- Mild eye discomfort\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (e.g., swelling, rash)\n- Persistent eye pain or inflammation\n- Sudden loss of vision\n- Corneal edema or ulceration\n- Acute anterior uveitis\n- Unexplained visual disturbances

Before initiating therapy, consider the following precautions.\n\nMonitor intra‑ocular pressure: measure regularly after starting treatment.\nAssess for ocular infections: avoid use if an active infection is present.\nAvoid contact lenses: discontinue lens wear during treatment and for several hours after instillation.\nCaution in patients with a history of uveitis: monitor closely for inflammation.\nPregnancy and breastfeeding: safety not established; use only if benefit outweighs risk.\nStore at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.\n\nMajor Interactions (Avoid):\n- Concurrent use of other prostaglandin analog eye drops: additive IOP‑lowering effect may cause excessive pressure reduction.\n- Non‑steroidal anti‑inflammatory eye drops: may diminish Latanoprost efficacy.\n- Systemic carbonic anhydrase inhibitors: additive IOP reduction risk.\n- Alpha‑adrenergic agonist eye drops: possible antagonistic effect on pressure control.\n- Duplicate prostaglandin therapy: avoid simultaneous use of multiple prostaglandin analogs.\n\nModerate Interactions (Monitor Closely):\n- Beta‑blocker eye drops: monitor for excessive IOP lowering.\n- Topical corticosteroids: may increase risk of ocular side effects.\n- Systemic NSAIDs: generally safe but monitor for any unexpected ocular response.